Get started
INTRA-CELLUAR THERAPIES INCINTRA-CELLUAR THERAPIES INCINTRA-CELLUAR THERAPIES INC

INTRA-CELLUAR THERAPIES INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ITCI chart


Full chart

ITCI upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪179.86 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−16.94 MXN
Net income (FY)
‪−2.37 B‬ MXN
Revenue (FY)
‪7.89 B‬ MXN
Shares float
‪99.11 M‬
Beta (1Y)
0.41

Employees


Employees (FY)
610
Change (1Y)
+49 +8.73%
Revenue / Employee (1Y)
‪12.93 M‬ MXN
Net income / Employee (1Y)
‪−3.89 M‬ MXN

About Intra-Cellular Therapies Inc.


Sector
Health Technology
CEO
Sharon L. Mates
Headquarters
Bedminster
Website
intracellulartherapies.com
Founded
2002
FIGI
BBG019ZNXRT3
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ITCI news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ITCI is 1,683.29 MXN — it has increased by 10.04% in the past 24 hours. Watch INTRA-CELLUAR THERAPIES INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange INTRA-CELLUAR THERAPIES INC stocks are traded under the ticker ITCI.
We've gathered analysts' opinions on INTRA-CELLUAR THERAPIES INC future price: according to them, ITCI price has a max estimate of 2,723.59 MXN and a min estimate of 1,755.20 MXN. Watch ITCI chart and read a more detailed INTRA-CELLUAR THERAPIES INC stock forecast: see what analysts think of INTRA-CELLUAR THERAPIES INC and suggest that you do with its stocks.
ITCI reached its all-time high on Dec 10, 2024 with the price of 1,683.29 MXN, and its all-time low was 939.32 MXN and was reached on Sep 27, 2023. View more price dynamics on ITCI chart.
See other stocks reaching their highest and lowest prices.
ITCI stock is 9.12% volatile and has beta coefficient of 0.41. Track INTRA-CELLUAR THERAPIES INC stock price on the chart and check out the list of the most volatile stocks — is INTRA-CELLUAR THERAPIES INC there?
Today INTRA-CELLUAR THERAPIES INC has the market capitalization of ‪179.86 B‬, it has decreased by −0.77% over the last week.
Yes, you can track INTRA-CELLUAR THERAPIES INC financials in yearly and quarterly reports right on TradingView.
INTRA-CELLUAR THERAPIES INC is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ITCI earnings for the last quarter are −4.93 MXN per share, whereas the estimation was −3.53 MXN resulting in a −39.48% surprise. The estimated earnings for the next quarter are −1.37 MXN per share. See more details about INTRA-CELLUAR THERAPIES INC earnings.
INTRA-CELLUAR THERAPIES INC revenue for the last quarter amounts to ‪3.46 B‬ MXN, despite the estimated figure of ‪3.39 B‬ MXN. In the next quarter, revenue is expected to reach ‪3.94 B‬ MXN.
ITCI net income for the last quarter is ‪−518.68 M‬ MXN, while the quarter before that showed ‪−297.51 M‬ MXN of net income which accounts for −74.34% change. Track more INTRA-CELLUAR THERAPIES INC financial stats to get the full picture.
No, ITCI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 610.00 employees. See our rating of the largest employees — is INTRA-CELLUAR THERAPIES INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTRA-CELLUAR THERAPIES INC EBITDA is ‪−2.39 B‬ MXN, and current EBITDA margin is −34.21%. See more stats in INTRA-CELLUAR THERAPIES INC financial statements.
Like other stocks, ITCI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTRA-CELLUAR THERAPIES INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTRA-CELLUAR THERAPIES INC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTRA-CELLUAR THERAPIES INC stock shows the strong buy signal. See more of INTRA-CELLUAR THERAPIES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.